Clinical Trial Update: Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 safety study of solanezumab in Japanese patients with Alzheimer's disease has completed, focusing on safety and tolerability in this population.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Solanezumab (solanezumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED